WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Ultragenyx Pharmaceutical earnings were -$532.9M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest RARE earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$115.0M, down 23.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RARE reported annual earnings of -$569.2M, with -6.2% growth.

RARE earnings history

Current Revenue
$610.2M
Current Earnings
-$532.9M
Current Profit Margin
-87.3%

RARE Return on Equity

Current Company
-245.1%
Current Industry
-9.6%
Current Market
32.2%
RARE's Return on Equity (-245.1%)... subscribe to Premium to read more.
High Return on Equity Performance

RARE undefined

Current Company
-37.7%
Current Industry
0%
RARE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RARE announces earnings.

RARE undefined

Current Company
-52.36%
Current Industry
7.7%
RARE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RARE vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RARE-$494.95M-$532.93MN/A-$5.52
CRNX-$321.95M-$328.25MN/A-$3.81
XENE-$278.10M-$278.23MN/A-$3.55
KYMR-$267.03M-$275.43MN/A-$3.48
ARWR-$57.42M-$143.97MN/A-$1.36
View Top Biotech Stocks

Ultragenyx Pharmaceutical Earnings Reports & History FAQ

What were Ultragenyx Pharmaceutical's earnings last quarter?

On RARE's earnings call on Invalid Date, Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q2 2025 earnings per share (EPS) of -$1.17, up 23.03% year over year. Total RARE earnings for the quarter were -$114.95 million. In the same quarter last year, Ultragenyx Pharmaceutical's earnings per share (EPS) was -$1.52.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

Is Ultragenyx Pharmaceutical profitable or losing money?

As of the last Ultragenyx Pharmaceutical earnings report, Ultragenyx Pharmaceutical is currently losing money. Ultragenyx Pharmaceutical's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$532.93 million, a 8.92% decrease year over year.

What was RARE's earnings growth in the past year?

As of Ultragenyx Pharmaceutical's earnings date in Invalid Date, Ultragenyx Pharmaceutical's earnings has grown year over year. RARE earnings in the past year totalled -$532.93 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.